Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Significance of IKZF1 deletions in pediatric ALL

Anthony Moorman • 22 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia

Anthony Moorman, PhD, Newcastle University, Newcastle, UK talks on IKZF1 (Ikarus) deletions in pediatric acute lymphoblastic leukemia (ALL) and whether it is still a poor prognostic marker, taking in account genetic context and minimal residual disease (MRD) at the end of induction therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anthony Moorman

Genomic profiling is redefining risk stratification in acute lymphoblastic leukemia
2:01
Genomic profiling is redefining risk stratification in acute lymphoblastic leukemia
Anthony Moorman • 13 Jun 2026
Predicting CNS relapse in ALL: integrating genetic and clinical risk factors
1:44
Predicting CNS relapse in ALL: integrating genetic and clinical risk factors
Anthony Moorman • 13 Jun 2026
Age and cytogenetics influence prognostic value of copy number profiles in B-cell ALL
1:48
Age and cytogenetics influence prognostic value of copy number profiles in B-cell ALL
Anthony Moorman • 12 Jun 2026
Future directions in ALL: targeted therapies and chemotherapy-free approaches
2:41
Future directions in ALL: targeted therapies and chemotherapy-free approaches
Anthony Moorman • 12 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals